Xeris Biopharma Holdings Inc (XERS)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Xeris Biopharma Holdings Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.

Xeris Biopharma Holdings is a commercial-stage biopharmaceutical company offering therapies for endocrine and neurological conditions in the United States. The company markets Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis, while advancing XP-8121, a once-weekly subcutaneous levothyroxine formulation for hypothyroidism.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Xeris Biopharma Holdings Inc stock.

Our verdict on XERS

Overvalued: intrinsic value $2.92 per share, market price $16.80, margin of safety -475.6% (as of 2026-11-17).

Discounting its cash flows at 8.8% values the shares at $2.92; the price of $16.80 is 476% above that value, and 78% of that value comes from beyond year five.

ETFs with the most weight in XERS

17 more funds hold it; the full list is part of the paid plan.

More on XERS

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than XERS in Drug Manufacturers - Specialty & Generic

29 more in this industry show a wider margin of safety.

Is XERS undervalued or overvalued?

XERS is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 8.8% values the shares at $2.92; the price of $16.80 is 476% above that value, and 78% of that value comes from beyond year five.

What is the intrinsic value of XERS?

$2.92 per share (as of the 2026-11-17 close), against a market price of $16.80. That is a margin of safety of -475.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.